Ad-hoc | 12 July 2017 20:01

aap Implantate AG: Result of Public Share Buyback Offer

aap Implantate AG / Key word(s): Share Buyback/Corporate Action

12-Jul-2017 / 20:01 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

aap Implantate AG announces that a total of 3,906,681 no-par value bearer shares of the company were offered for repurchase to the company within the acceptance period of the voluntary public share buyback offer from 20 June 2017, 00.00 hours (CEST) until 10 July 2017, 24.00 hours (CEST). Thereby the share buyback offer of aap Implantate AG was oversubscribed. The shareholders’ declarations of acceptance are therefore taken into account proportionally in accordance with Section 3.3 of the offer document.

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) – Prime Standard/Regulated Market – All German stock markets –

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven’t yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG’s stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company’s investor relations app from the Apple’s App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap ‘s public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

Contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 134; Fax.: ++49/30/750 19 – 290; f.franke@aap.de

12-Jul-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	aap Implantate AG
	Lorenzweg 5
	12099 Berlin
	Germany
Phone:	+49 (0) 30 75 01 90
Fax:	+49 (0) 30 75 01 91 11
E-mail:	info@aap.de
Internet:	www.aap.de
ISIN:	DE0005066609
WKN:	506660
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

End of Announcement DGAP News Service